Publications by authors named "Khaldoon Al-Humood"
Article Synopsis
- The study evaluates the cost-effectiveness of Sodium zirconium cyclosilicate (SZC) compared to patiromer in managing serum potassium levels in patients with chronic kidney disease (CKD) and heart failure (HF) from a Kuwaiti healthcare perspective.
- A comprehensive simulation model was used to analyze the clinical outcomes and costs associated with both treatments over a lifetime horizon, using data from significant clinical trials and local hospital costs.
- Results indicate that SZC is generally a cost-saving treatment option for managing hyperkalemia, with potential savings ranging from KWD -60 to KWD -1,235, suggesting it should be considered as a viable treatment for CKD/HF patients in Kuwait.
Although epidemiological data on heart failure (HF) with preserved ejection fraction (HFpEF) are scarce in the Middle East, North Africa and Turkey (MENAT) region, Lancet Global Burden of Disease estimated the prevalence of HF in the MENAT region in 2019 to be 0.78%, versus 0.71% globally.
View Article and Find Full Text PDFBackground: Heart Failure is an epidemic with a current prevalence of over 5.8 million patients in the USA and almost 23 million patients worldwide, with high associated mortality risks. The severe shortage of donor organs for cardiac transplants and increasing number of heart failure patients has led to the increasing popularity of left ventricular assist device (LVAD) therapy for treatment of end-stage heart failure patients.
View Article and Find Full Text PDFBackground: We analyzed the low-dose (1 microg) rapid adrenocorticotropic hormone test (LDST) in 17 patients with a normal hypothalamic-pituitary-adrenal axis to determine reference intervals for the LDST on the basis of poststimulation cortisol increments.
Methods: We analyzed test results for 17 patients (14 females and 3 males; age range, 18-46 years) who had received a 2-mL aliquot of low-dose (1 microg) adrenocorticotropic hormone prepared from one 250-microg vial of Synacthen diluted in 500 mL of sterile normal saline solution. Sampling took place at 0, 20, 30, and 60 min post stimulation.